Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes ABSI: money market or bond funds, or no holdings data yet
30 Dec 2025 → 3 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| ABSI | +186.53% | 106.50% | 1.75 |
| ES-GENOME | +64.37% | 42.32% | 1.52 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | ABSI | ES-GENOME |
|---|---|---|
Fund details | ||
| Fund size | N/A | 225 million |
| Inception date | N/A | 23 Mar 2021 |
| Master fund | N/A | กองทุนที่ลงทุนหลายกอง (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) |
| Dividend policy | N/A | Does not pay |
Risk and currency hedging | ||
| Risk level | N/A | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion |
| Share hedged | N/A | 79.06% |
Minimum purchase and redemption | ||
| First purchase | N/A | 1 THB |
| Subsequent purchase | N/A | 1 THB |
| Redemption (amount) | N/A | 1 THB |
| Redemption (units) | N/A | 1 units |
| Balance (amount) | N/A | No minimum |
| Balance (units) | N/A | No minimum |
Order cut-off and redemption payment | ||
| Buy before | N/A | 15:30 |
| Redeem before | N/A | 15:30 |
| Redemption paid | N/A | T+4 |
